Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02390960 · ClinicalTrials.gov registry record · Phase 2
Phase 2a Topical Sildenafil Proof-of-Concept Study in Men With Mild to Moderate ED
A Phase 2 study, sponsored by Strategic Science & Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT02390960 is a Phase 2 study that has completed, run by Strategic Science & Technologies. The registered enrollment target is 33 participants.
The verdict
NCT02390960, a Phase 2 study, has completed, sponsored by Strategic Science & Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a Phase 2a, single-dose, double-blind, placebo-controlled, 2-way crossover study in men with ED. A single 2 gram dose of SST-6006 topical cream 5% w/w (formulated to deliver 100 mg of sildenafil) or a topical placebo cream will be applied to the penile shaft and glans. There are 4 study phases: the Initial Patient Screening Phase (Visit 1, an Off Site 4-Week Run-in Period and Visit 2), the Final Patient Screening Phase (Visit 3), the SST-6006/Placebo Double-Blind Dosing Phase (Visits 4-5), and the Follow-up Phase. Primary outcomes will be be evaluated at Weeks 7 and 8 of the study
Interventions
- DRUG Placebo Cream
- DRUG Sildenafil Cream
- DEVICE Penile Plethysmography (RigiScan)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02390960
The ClinicalTrials.gov registry entry for NCT02390960 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Strategic Science & Technologies, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Cream is the first listed.
NCT02390960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02390960 about?
NCT02390960 is a clinical study titled "Phase 2a Topical Sildenafil Proof-of-Concept Study in Men With Mild to Moderate ED". This is a Phase 2a, single-dose, double-blind, placebo-controlled, 2-way crossover study in men with ED. A single 2 gram dose of SST-6006 topical cream 5% w/w (formulated to deliver 100 mg of sildenafil) or a topical placebo cream will be applied to the penile shaft and glans. There are 4 study phas...
What is the current status of trial NCT02390960?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2015-03. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02390960?
The interventions under investigation include: Placebo Cream (DRUG), Sildenafil Cream (DRUG), Penile Plethysmography (RigiScan) (DEVICE).
Who is sponsoring clinical trial NCT02390960?
This trial is sponsored by Strategic Science & Technologies, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.